Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID)

PHASE4CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Remodulin

Treatment will be initiated whilst hospitalized at approximately 2.0 ng/kg/min with dose increments of 1- 2 ng/kg/min approximately every 12 hours according to clinical response and tolerability. Following subject discharge, the dose rate is increased by 1-2 ng/kg/min with dose increments separated by at least 24 hours. When a dose rate of 20 ng/kg/min is achieved dose increments can be increased at a rate of up to 4 ng/kg/min with dose increments separated by at least 24 hours depending on tolerability. The aim is to achieve a dose rate of at least 10, 20 and 30 ng/kg/min by the end of weeks 1, 4 and 12, respectively and a dose rate by the end of week 16 that achieves pre-defined treatment goals subject to clinical response and tolerability.

Sponsors
All Listed Sponsors
lead

United Therapeutics

INDUSTRY

NCT02847260 - Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID) | Biotech Hunter | Biotech Hunter